Odomzo

Chemical Namesonidegib
Dosage FormCapsule (oral; 200 mg)
Drug ClassInhibitors
SystemSkin
CompanySun Pharma Global
Approval Year2015

Indication

  • To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Odomzo (sonidegib) Prescribing Information2019Sun Pharmaceutical Industries, Inc., Cranbury, NJ